{
    "clinical_study": {
        "@rank": "8374", 
        "arm_group": [
            {
                "arm_group_label": "ABT-981 low dose", 
                "arm_group_type": "Active Comparator", 
                "description": "Low dose"
            }, 
            {
                "arm_group_label": "ABT-981 medium dose", 
                "arm_group_type": "Active Comparator", 
                "description": "Medium dose"
            }, 
            {
                "arm_group_label": "ABT-981 high dose", 
                "arm_group_type": "Active Comparator", 
                "description": "High dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase 2a, multicenter, randomized, double-blind, parallel group, placebo-controlled study\n      to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic effect of\n      ABT-981 in patients with symptomatic, radiographic, and inflammatory knee osteoarthritis."
        }, 
        "brief_title": "A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Knee Osteoarthritis", 
            "Medial Compartment Knee Osteoarthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Radiographic knee osteoarthritis with Kellgren-Lawrence Grade 2 or 3\n\n          2. Body Mass Index (BMI) 18-34 kg/m2\n\n          3. One or more clinical signs and symptoms of active inflammation in the index knee\n\n        Exclusion Criteria:\n\n          1. History of allergic reaction to any constituents of the study drug, or to any\n             Immunoglobulin G (IgG)-containing product\n\n          2. History of anaphylactic reaction to any agent\n\n          3. Significant trauma or surgery to the index knee\n\n        3. Severe knee malalignment 4. Any uncontrolled medical illness or an unstable treatment\n        or therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087904", 
            "org_study_id": "M13-741", 
            "secondary_id": "2013-003467-60"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ABT-981 low dose", 
                    "ABT-981 medium dose", 
                    "ABT-981 high dose"
                ], 
                "intervention_name": "ABT-981", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pain", 
            "Osteoarthritis", 
            "Synovitis", 
            "Knee"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "Site Reference ID/Investigator# 119796"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 119796", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96814"
                    }, 
                    "name": "Site Reference ID/Investigator# 121618"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 121618", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Site Reference ID/Investigator# 119397"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 119397", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Site Reference ID/Investigator# 119587"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 119587", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00909-3004"
                    }, 
                    "name": "Site Reference ID/Investigator# 120576"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 120576", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Puerto Rico"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis", 
        "overall_contact": {
            "email": "margaret.wojtecka@abbvie.com", 
            "last_name": "Margaret   Wojtecka", 
            "phone": "847-937-0494"
        }, 
        "overall_contact_backup": {
            "email": "Sara.Gibbs@abbvie.com", 
            "last_name": "Sara  Gibbs", 
            "phone": "847-938-5302"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Susanne   Wang, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "It is evaluated using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).", 
                "measure": "Changes in Pain Score of the index knee", 
                "safety_issue": "No", 
                "time_frame": "From Day 1 to Week 16"
            }, 
            {
                "description": "It is evaluated using quantitative and semiquantitative Magnetic Resonance Imaging (MRI) measurements.", 
                "measure": "Change in synovitis/effusion volume of the index knee", 
                "safety_issue": "No", 
                "time_frame": "From Day 1 to Week 26"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087904"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "It is evaluated using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).", 
                "measure": "Change in physical function", 
                "safety_issue": "No", 
                "time_frame": "From Day 1 to Week 52"
            }, 
            {
                "description": "It is evaluated using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).", 
                "measure": "Change in index knee pain", 
                "safety_issue": "No", 
                "time_frame": "From Day 1 to Week 52"
            }, 
            {
                "description": "It is evaluated in Magnetic Resonance Imaging (MRI).", 
                "measure": "Change in bone marrow lesions of the index knee", 
                "safety_issue": "No", 
                "time_frame": "From Day 1 to Week 52"
            }, 
            {
                "description": "It is evaluated using the Intermittent and Constant Osteoarthritis Pain (ICOAP) score", 
                "measure": "Change in index knee Intermittent and Constant Pain", 
                "safety_issue": "No", 
                "time_frame": "From Day 1 to Week 52"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}